medwireNews

Previously untreated patients with PD-L1-positive advanced non-small-cell lung cancer could benefit from the combination of tiragolumab plus atezolizumab, indicate phase 2 trial data.

EULAR has put forward “points to consider” that aim to guide the integration of telehealth into rheumatology clinical practice.

Glucagon-like peptide-1 receptor agonists may delay the incidence of major adverse cardiovascular events by an average of 0.6 months over a 4-year period in people with type 2 diabetes, meta-analysis data suggest.

Around a quarter of phase 3 randomized controlled trials for advanced cancer show an improvement in global quality of life and this is significantly linked to improvements in overall survival, Canadian researchers say.

Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.

Find out more about the recommendations on exercise, diet, and weight management here